Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

Release Date: September 30, 2025

Expiration Date: September 30, 2026

Activity Overview

Standard-of-care, first-line treatment of advanced melanoma consists of dual immune checkpoint inhibitor (ICI) therapy. Available second-line options for patients who progress on first-line treatment include alternate ICI treatment, adoptive cell therapy, and oncolytic virus therapy, each of which has its benefits and challenges.

This Community Practice Connections™ program provides an in-depth review of some of the key highlights from an Association of Cancer Care Centers virtual webcast series on oncolytic immunotherapy in melanoma. This unique and engaging multimedia activity is ideal for the community-based clinician. It focuses on current and emerging second-line therapies for treating advanced melanoma, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learning for those who did.

Target Audience

This educational program is directed toward community-based medical oncologists, interventional radiologists, surgeons, nurse practitioners, nurses, pharmacists, and other health care professionals who treat advanced melanoma.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Evaluate clinical and safety data for second-line therapies in melanoma, including oncolytic viruses, tumor-infiltrating lymphocytes, and combination immunotherapies, in patients with progression on PD-1 inhibitors.
• Describe the mechanistic rationale, administration techniques, and clinical benefits of oncolytic viruses in advanced melanoma.
• Apply best practices for multidisciplinary care of patients receiving intratumoral oncolytic immunotherapies, including coordination between medical oncologists, interventional radiologists, nurse practitioners, nurses, pharmacists, and surgical oncologists.